Cargando…

Periostin is a novel histological biomarker for the diagnosis of chondroid tumor

BACKGROUND: The chondroid tumor is generally classified into three types, enchondroma, low-grade chondrosarcoma, and high-grade chondrosarcoma. A histological evaluation of a biopsy sample is the best predictor of the clinical course in most patients with carcinomas or sarcomas. Sometimes serologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dough, Jeong, Ji Yun, Han, Man-Hoon, Chae, Jongmin, Park, Ilhyung, Yoon, Jongphil, Kyung, Heesoo, Kim, Ha-Jeong, Jeong, Wonju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798228/
https://www.ncbi.nlm.nih.gov/pubmed/35116273
http://dx.doi.org/10.21037/tcr-20-2499
_version_ 1784641749796257792
author Kim, Dough
Jeong, Ji Yun
Han, Man-Hoon
Chae, Jongmin
Park, Ilhyung
Yoon, Jongphil
Kyung, Heesoo
Kim, Ha-Jeong
Jeong, Wonju
author_facet Kim, Dough
Jeong, Ji Yun
Han, Man-Hoon
Chae, Jongmin
Park, Ilhyung
Yoon, Jongphil
Kyung, Heesoo
Kim, Ha-Jeong
Jeong, Wonju
author_sort Kim, Dough
collection PubMed
description BACKGROUND: The chondroid tumor is generally classified into three types, enchondroma, low-grade chondrosarcoma, and high-grade chondrosarcoma. A histological evaluation of a biopsy sample is the best predictor of the clinical course in most patients with carcinomas or sarcomas. Sometimes serological or molecular markers are used as prediction markers, but there has been no reliable marker for chondroid tumor diagnosis. Clinical and radiological, but not histological features, are still used in the diagnosis and staging of chondroid tumors. During a histopathological diagnosis, it has been difficult to distinguish between benign enchondroma and low-grade chondrosarcoma. To allow for more accurate treatments, new histological biomarkers for the differential diagnosis are needed. METHODS: Twenty-eight cases of enchondromas and thirty-three cases of low-grade chondrosarcoma were selected. Thirteen cases of non-tumorous cartilage were used for the control group, who underwent artificial joint surgery for degenerative arthritis. Surgically removed tissue specimens were formalin-fixed paraffin-embedded and hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stains were performed. RESULTS: Periostin was expressed in chondroid tumors but not in the normal cartilage. Periostin was observed via immunostaining in the cytoplasm but not in the extracellular matrix of enchondroma tissue, and was observed in the cytoplasm and extracellular matrix of low-grade chondrosarcoma. The sensitivity and specificity of these stains were 93.9% and 96.4%, respectively. CONCLUSIONS: Based on these results, we suggest that periostin could be used as a novel prognostic marker to distinguish between enchondroma and low-grade chondrosarcoma.
format Online
Article
Text
id pubmed-8798228
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87982282022-02-02 Periostin is a novel histological biomarker for the diagnosis of chondroid tumor Kim, Dough Jeong, Ji Yun Han, Man-Hoon Chae, Jongmin Park, Ilhyung Yoon, Jongphil Kyung, Heesoo Kim, Ha-Jeong Jeong, Wonju Transl Cancer Res Original Article BACKGROUND: The chondroid tumor is generally classified into three types, enchondroma, low-grade chondrosarcoma, and high-grade chondrosarcoma. A histological evaluation of a biopsy sample is the best predictor of the clinical course in most patients with carcinomas or sarcomas. Sometimes serological or molecular markers are used as prediction markers, but there has been no reliable marker for chondroid tumor diagnosis. Clinical and radiological, but not histological features, are still used in the diagnosis and staging of chondroid tumors. During a histopathological diagnosis, it has been difficult to distinguish between benign enchondroma and low-grade chondrosarcoma. To allow for more accurate treatments, new histological biomarkers for the differential diagnosis are needed. METHODS: Twenty-eight cases of enchondromas and thirty-three cases of low-grade chondrosarcoma were selected. Thirteen cases of non-tumorous cartilage were used for the control group, who underwent artificial joint surgery for degenerative arthritis. Surgically removed tissue specimens were formalin-fixed paraffin-embedded and hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stains were performed. RESULTS: Periostin was expressed in chondroid tumors but not in the normal cartilage. Periostin was observed via immunostaining in the cytoplasm but not in the extracellular matrix of enchondroma tissue, and was observed in the cytoplasm and extracellular matrix of low-grade chondrosarcoma. The sensitivity and specificity of these stains were 93.9% and 96.4%, respectively. CONCLUSIONS: Based on these results, we suggest that periostin could be used as a novel prognostic marker to distinguish between enchondroma and low-grade chondrosarcoma. AME Publishing Company 2021-01 /pmc/articles/PMC8798228/ /pubmed/35116273 http://dx.doi.org/10.21037/tcr-20-2499 Text en 2021 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Original Article
Kim, Dough
Jeong, Ji Yun
Han, Man-Hoon
Chae, Jongmin
Park, Ilhyung
Yoon, Jongphil
Kyung, Heesoo
Kim, Ha-Jeong
Jeong, Wonju
Periostin is a novel histological biomarker for the diagnosis of chondroid tumor
title Periostin is a novel histological biomarker for the diagnosis of chondroid tumor
title_full Periostin is a novel histological biomarker for the diagnosis of chondroid tumor
title_fullStr Periostin is a novel histological biomarker for the diagnosis of chondroid tumor
title_full_unstemmed Periostin is a novel histological biomarker for the diagnosis of chondroid tumor
title_short Periostin is a novel histological biomarker for the diagnosis of chondroid tumor
title_sort periostin is a novel histological biomarker for the diagnosis of chondroid tumor
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798228/
https://www.ncbi.nlm.nih.gov/pubmed/35116273
http://dx.doi.org/10.21037/tcr-20-2499
work_keys_str_mv AT kimdough periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT jeongjiyun periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT hanmanhoon periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT chaejongmin periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT parkilhyung periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT yoonjongphil periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT kyungheesoo periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT kimhajeong periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor
AT jeongwonju periostinisanovelhistologicalbiomarkerforthediagnosisofchondroidtumor